Skip to content
Press Releases
Filter Releases
 
Press Releases
Oct 18, 2013
South San Francisco, Calif. --- October 18, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced preliminary study results suggesting the potential for an RNA-based gene expression test to accurately detect the BRAF V600E gene mutation in thyroid nodule fine needle aspiration (FNA) sam...
PDF
Sep 20, 2013
South San Francisco, Calif. – September 20, 2013 - Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc. The numb...
PDF
Jul 8, 2013
South San Francisco, Calif. --- July 8, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that Aetna, the third largest health plan in the United States, has issued a positive coverage policy for the company’s Afirma Gene Expression Cl...
PDF
Jun 28, 2013
South San Francisco, Calif. --- June 28, 2013 --- Veracyte, Inc., a molecular diagnostics company in the field of molecular cytology, today announced the completion of the final tranche of its $28 million Series C financing. The financing included GE Ventures as a new investor, as well as existing investors...
PDF
Apr 17, 2013
South San Francisco, Calif. --- April 17, 2013 --- A new study shows that the number of patients with thyroid nodules who undergo surgery – increasingly to remove all, rather than part, of their thyroid – has risen by 31% over five years, Veracyte announced today. The findings suggest that growi...
PDF
Apr 12, 2013
South San Francisco, Calif. --- April 12, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer. “We are delighted to welcome Shelly Guyer to the Veracyte team,...
PDF
Mar 12, 2013
South San Francisco, Calif. --- March 12, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced new study findings showing that when BRAF V600E mutation testing was conducted on ambiguous thyroid nodule samples that were subsequently cl...
PDF
Mar 8, 2013
South San Francisco, Calif. --- March 8, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that UnitedHealthcare, one of the nation’s largest private health insurers, has issued a positive medical coverage policy for the Afi...
PDF
Feb 15, 2013
South San Francisco, Calif. --- February 15, 2013 --- Veracyte, Inc. today announced that a new review article published in PLOS Currents: Evidence on Genomic Tests concludes that published studies and independent assessments and reviews...
PDF
Jan 7, 2013
South San Francisco, Calif. --- January 7, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that, for the first time, molecular testing is now included in the National Comprehensive Cancer Network Clinical Practice Guidelines in ...
PDF
Page: First Previous
...
Next Last